Eat Just

Eat Just is the rare food-tech company with a genuine hit product and a moonshot option attached. JUST Egg, its mung-bean liquid egg replacement, is the dominant U.S. plant-based egg brand, and the timing has become extraordinary: recurring avian-flu outbreaks have sent conventional egg prices soaring, and CEO Josh Tetrick reports the product growing roughly five times faster year-over-year, with inbound demand from the U.S. military, convenience chains, restaurants, and fast-food — and, tellingly, 91% of buyers are not vegetarian or vegan. Tetrick says every case sells at a positive margin, and the company is pushing JUST Egg into Europe via a deal with VFG. The second act is the option value: through GOOD Meat, Eat Just was the first company anywhere to win regulatory approval to sell cultivated meat, launching cultured chicken in Singapore in 2020 and later securing U.S. clearance — a first-mover position in cell-based protein that no competitor can retroactively claim. It has raised more than $850M total (about $270M earmarked for GOOD Meat). A profitable-at-the-margin, fast-growing egg business riding a structural avian-flu tailwind, paired with a pioneering cultivated-meat call option, is a far more grounded story than most alt-protein names can tell.

Eat Just's two businesses are each a caution. JUST Egg is growing on the back of avian-flu-driven egg-price spikes — a cyclical windfall, not a structural moat; when flocks recover and conventional egg prices fall, the value proposition of a premium plant-based substitute erodes, and the company itself concedes the product portfolio is currently not profitable even as individual cases sell at positive margin. Eat Just laid off around 40 staff in its egg division in 2025 to cut costs, hardly the posture of a business in comfortable control of its economics. GOOD Meat, the moonshot, has consumed roughly $270M and remains a capital sink: it faces the same unresolved cost and scale-up problems as the entire cultivated-meat field, targets "tens of millions of pounds before the end of the decade" — a distant, aspirational figure — and operates against a backdrop of U.S. state-level cultivated-meat bans and evaporating category funding. Being first to approval bought bragging rights, not a profitable business. Across both divisions, Eat Just has raised over $850M in more than a decade without reaching durable profitability, and its fortunes are now tethered to an avian-flu tailwind it doesn't control on one side and a cash-hungry cultivated bet with no clear path to scale on the other.